Welcome to our dedicated page for EKWIF news (Ticker: EKWIF), a resource for investors and traders seeking the latest updates and insights on EKWIF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EKWIF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EKWIF's position in the market.
Everkind Wellness (EKWIF) has received approval for quotation of its common shares on the OTCQB Venture Market, with trading expected to begin on September 17, 2026 under the symbol “EKWIF”.
The company’s shares will continue to trade on the TSX Venture Exchange under “EK”, and the OTCQB quotation does not involve a new securities issuance or dilution for existing shareholders. The listing is intended to give U.S. investors improved access and transparency when trading Everkind shares through U.S. brokerage accounts. In connection with this, Everkind has applied for DTC eligibility in the United States, although the timing and outcome of that application remain uncertain.